Results 181 to 190 of about 2,511,430 (316)

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

open access: yesMolecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa   +14 more
wiley   +1 more source

ECM-Preserving Decellularization of Dermis via Subtle Cell Membrane Disruption Induced by Subcritical Dimethyl Ether. [PDF]

open access: yesACS Omega
Nakamura N   +7 more
europepmc   +1 more source

Adenosine Triphosphatase in Isolated Bacterial Cell Membranes

open access: hybrid, 1960
Adolph Abrams   +2 more
openalex   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Breaking Barriers in Glioblastoma Targeting through Advanced Nanoparticle Cell Membrane Coating. [PDF]

open access: yesACS Appl Mater Interfaces
Jiménez-Boland D   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy